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Abstract
AIM: To investigate influence of human leukocyte an-
tigen (HLA) and killer immunoglobuline-like receptor 
(KIR) genotypes on risks of acute rejection (AR) after 
liver transplantation (LTX). 
METHODS: In this retrospective study we included 
143 adult donor-recipient pairs with a minimum of 6 
mo follow-up after LTX for whom DNA was available 
from both donor and recipients. Clinical data, all early 
complications including episodes and severity of AR and 
graft/patient survival were registered. The diagnosis 
of AR was based on clinical, biochemical and histologi-
cal criteria. All suspected episodes of AR were biopsy 
confirmed. Key classical HLA loci (HLA-A , HLA-B , HLA-C  
and HLA-DRB1) were genotyped using Sanger sequenc-
ing. 16 KIR genes were genotyped using a novel real 
time PCR approach which allows for determination of 
the diploid copy number of each KIR gene. Immunohis-
tochemical staining for T (CD3), B (CD20) and natural 
killer (NK) cells (CD56 and CD57) were performed on 
liver biopsies from 3 different patient groups [primary 
sclerosing cholangitis (PSC), primary biliary cirrhosis 
and non-autoimmune liver disease], 10 in each group, 
with similar grade of AR.
RESULTS: Fourty-four (31%) patients were transplant-
ed on the basis of PSC, 40% of them had AR vs  24% 
in the non-PSC group (P  = 0.04). No significant impact 
of donor-recipient matching for HLA and KIR geno-
types was detected. In the overall recipient population 
an increased risk of AR was detected for HLA-B*08 (P  
= 0.002, OR = 2.5; 95%CI: 1.4-4.6), HLA-C*07 (P  = 
0.001, OR = 2.4; 95%CI: 1.4-4.0) and HLA-DRB1*03 
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shown different frequencies (range 11%-80%) of  AR af-
ter LTX, but consistently the incidence of  AR in patients 
transplanted on the basis of  primary sclerosing cholangitis 
(PSC) is increased (range 17%-100%) compared to other 
groups[3-6]. Patients treated for non-autoimmune liver 
diseases (e.g., alcoholic liver disease or fulminant hepatic 
failure from paracetamol intoxication) seem to have a low 
risk of  AR[2,6-8]. Analyses of  variables affecting AR risk 
after LTX have been inconsistent, and whether match-
ing of  donor and recipient for human leukocyte antigen 
(HLA) influences AR occurrence after LTX remains con-
troversial[9-12]. The increased risk of  AR in PSC patients 
after LTX is clinically important because increased im-
munosuppression is needed with concomitant side effects. 
Rejection episodes in PSC patients may also increase the 
risk for recurrent PSC in the liver allograft[5,13-15]. 
HLA class Ⅰ molecules interact specifically with T-cell 
receptors (TCR) upon binding of  antigenic peptides, 
and they (HLA-B and HLA-C in particular) can also act 
as ligands for killer-cell immunoglobulin-like receptors 
(KIR) expressed on natural killer (NK) cells and subsets 
of  T-cells[16-18]. The interaction between the genetically 
determined HLA-C2 variant and its corresponding KIRs 
delivers a more potent inhibitory signal to NK cells than 
HLA-C1[16]. The potential benefit of  incorporating ge-
netic killer immunoglobulin-like (KIR) variation when 
assessing the impact of  HLA matching on AR risk is not 
clear[19-23]. The major biological role of  the HLA-KIR 
interaction is to influence activation status in various con-
texts of  NK cell and T cell function (e.g., cytotoxicity)[16]. 
The HLA-C/KIR interactions have been studied exten-
sively in HLA-related[24,25] and unrelated[26,27] hematopoi-
etic stem cell transplantation (HSCT). 
There is evidence to suggest that the influence of  
HLA on AR risk is not uniform in all recipients and that 
stratification for the presence of  underlying autoim-
mune liver diseases with known HLA associations may 
influence results[12,28]. PSC is strongly HLA-associated[29], 
with the peak association signal mapping to the HLA 
class Ⅰ region (HLA-B*08 in particular), but there are 
also significant residual effects within class Ⅱ, likely rep-
resented by several HLA-DRB1 alleles (i.e., DRB1*13:01, 
DRB1*03:01, DRB1*04, DRB1*07 and DRB1*11)[30-33], 
or variants in linkage disequilibrium with these. Two stud-
ies also suggest that genetic variation affecting the bind-
ing of  class Ⅰ molecules to KIRs contribute to the HLA 
associations in PSC[34,35]. 
In this study we aimed to explore the influence of  
HLA and KIR genotypes on AR risk after LTX with par-
ticular emphasis on patients transplanted for PSC com-
pared to recipients with other underlying liver diseases.
MATERIALS AND METHODS
Patients 
All patients undergoing LTX between 1996 and 2008 at 
Oslo University Hospital, Rikshospitalet, Norway were 
included in a retrospective design. A total of  520 LTX 
3987 April 14, 2014|Volume 20|Issue 14|WJG|www.wjgnet.com
Fosby B et al . HLA and rejection in liver transplantation
risk for HLA-DRB1*04 (P  = 0.001, OR = 0.2; 95%CI: 
0.1-0.5). For HLA-B*08, HLA-C*07 and DRB1*04 the 
associations remained evident in a subgroup analysis of 
non-PSC recipients (P  = 0.04, P  = 0.003 and P  = 0.02, 
respectively). In PSC recipients corresponding P  values 
were 0.002, 0.17 and 0.01 for HLA-B*08, HLA-C*07 
and DRB1*04, respectively. A dosage effect of AR 
prevalence according to the PSC associated HLA alleles 
was also notable in the total recipient population. For 
HLA-B*08 the frequency of AR was 56% in HLA-B*08 
homozygous recipients, 39% in heterozygous recipients 
and 21% in recipients lacking HLA-B*08 (P  = 0.02). 
The same was observed for the HLA-C*07 allele with 
AR in 57%, 27% and 18% in recipients being homozy-
gous, heterozygous and lacking HLA-C*07 respectively 
(P  = 0.003). Immunohistochemical analysis showed 
similar infiltration of T, B and NK cells in biopsies with 
AR in all three groups. 
CONCLUSION: We found significant associations be-
tween the PSC-associated HLA-B*08, HLA-C*07, HLA-
DRB1*03 and HLA-DRB1*04 alleles and risk of AR in 
liver transplant recipients. 
© 2014 Baishideng Publishing Group Co., Limited. All rights 
reserved.
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Core tip: Patients undergoing liver transplantation on 
the basis of primary sclerosing cholangitis (PSC) have 
a higher frequency of acute cellular rejections than 
non-PSC patients. Recent studies have determined the 
genetic susceptibility to PSC, of which genetic variants 
in the human leukocyte antigen complex represent the 
strongest risk factors. In the present report we show 
that these variants also influence risk of acute cellular 
rejection after liver transplantation in PSC. Moreover, 
we show that the same variants also involve in risk of 
acute cellular rejection in non-PSC recipients.
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INTRODUCTION
Liver transplantation (LTX) is the only curative treatment 
for end-stage liver disease[1]. Although both graft and pa-
tient survival have improved dramatically over the last two 
decades, acute rejection (AR) still represents a significant 
clinical problem[2-5]. Numerous studies over the years have 
were performed during this period and for 198 donor/
recipient pairs archival DNA samples were available for 
HLA and KIR genotyping. We included all patients above 
12 years that received a first liver graft from a deceased 
donor and with a minimum follow-up period of  six 
months (n = 176). Patients with early graft loss (< 30 d) 
resulting from primary dysfunction or vascular compli-
cations without evidence of  AR were excluded (n = 7). 
Patients receiving ABO incompatible liver or those with a 
combined liver/kidney transplantation were also excluded 
(n = 4). To minimize the impact of  confounders, we 
excluded patients with uncertain or inconclusive biopsy 
results and patients treated for AR based on clinical/bio-
chemical suspicion only, without a confirmatory biopsy 
(n = 17; 8 PSC, 3 autoimmune hepatitis, 1 hepatitis C cir-
rhosis, 2 hepatitis C cirrhosis, 2 alcoholic cirrhosis, 1 pri-
mary biliary cirrhosis). Finally we also excluded 5 patients 
who received immunosuppressive regimens according to 
obsolete protocols (calcineurin inhibitor in combination 
with azathioprine and prednisolone).
The final study population comprised 143 adult re-
cipients (82 males, 61 females) with a median age of  52 
years (range 13 to 73 years). PSC patients constituted the 
largest group of  liver recipients (n = 45). The diagnosis 
of  PSC was in all cases made based on standard diagnos-
tic criteria[36]. The study protocol received prior approval 
by the regional ethics committee (reference number 
S-08873b). Written informed consent concerning the 
use of  biopsy/DNA material was obtained from all re-
cipients still alive. The research ethics committee granted 
exemption from consent for recipients deceased at time 
of  study initiation. Furthermore, the Norwegian Health 
Directorate approved the utilization of  DNA samples 
from the deceased donors (reference number 08/10827). 
Clinical data
By thorough investigation of  all patient records, blood 
tests, radiology results and histology assessments, we 
determined indications for LTX, number and severity 
of  episodes of  AR [Banff  rejection activity index (RAI) 
scoring, steroid responsive/non-responsive], graft sur-
vival and overall patient survival. Immunosuppression 
consisted of  standard triple-drug therapy with tacrolimus, 
prednisolone and mycophenolate mofetil. Tacrolimus 
(or cyclosporin) was given on the first day after LTX and 
adjusted according to daily blood concentrations. Meth-
ylprednisolone was administered perioperatively at a dos-
age of  500 mg, subsequently tapered to 20 mg/d during 
the first week and gradually to 5 mg/d within 6 mo. My-
cophenolate was given at an initial dose of  1000 mg twice 
daily. 
The diagnosis of  AR was based on clinical, biochemi-
cal and histological criteria. According to routine practice 
at our center, all patients were monitored by daily blood 
samples and any increase in liver enzymes or bilirubin re-
sulted in examination with liver sonography with doppler 
to determine the presence of  circulatory or anatomical 
complications. After clinical exclusion of  circulatory and 
surgical causes of  detected abnormalities in liver enzymes 
and/or bilirubin, a liver biopsy was carried out. All sus-
pected episodes of  AR included in this study were biopsy 
confirmed and classified by rejection activity index (RAI) 
according to the Banff  1997 standard[37]. All but two bi-
opsies, which showed severe AR, were classified as either 
mild (RAI 3-4) or moderate (RAI 5-6). Ten patients (5 
PSC, 2 primary biliary cirrhosis (PBC), 1 hepatocellular 
carcinoma, 1 cholangiocarcinoma and 1 hepatitis C infec-
tion) had steroid-resistant AR (after 3-4 pulses of  meth-
ylprednisolone over 3-4 consecutive days, total dose of  
2-2.5 g) and were subsequently treated with antithymo-
cyte globuline (ATG) according to protocol. 
HLA-genotyping
HLA-A, -B, -C (class Ⅰ) and -DRB1 (class Ⅱ) typing 
was performed using previously described sequencing-
based typing protocols at Institute for Immunology, Oslo 
University Hospital, Rikshospitalet, Norway[34]. Ambigu-
ous HLA types were excluded from analysis (1 patient 
HLA-B, 1 patient HLA-C).
KIR-genotyping
KIR genotyping was performed using a novel method 
allowing accurate determination of  copy number varia-
tion (CNV) of  each KIR gene based on a triplex real-time 
PCR approach[38]. 14 KIR-genes and 2 pseudogenes were 
genotyped for each sample in quadruplicate; samples 
with ≤ 1 successful replicate were excluded. Calling of  
copy numbers was verified manually in CopyCaller v.1.0 
(Applied Biosystems, Foster City, CA, United States) and 
results imported into Microsoft Excel (Redmond, WA, 
United States). Copy numbers > 4 were excluded and all 
0 copies were verified by amplification of  the reference 
gene. 
Immunohistochemistry
To expand on the genetic analysis of  KIR genes, also 
considering the conflicting results in previously published 
experiments[19-23], an immunohistochemical determination 
of  the number of  NK cells as compared with T- and B 
cells in liver allograft biopsies with AR were performed. 
Archival biopsy material from 10 patients with PSC, 10 
patients with PBC and 10 patients with non-immunolog-
ical liver diseases (3 alcoholic cirrhosis, 1 polycystic liver 
disease, 2 cryptogenic cirrhosis, 1 Budd Chiari and 3 with 
colorectal liver metastases) were examined. All selected 
biopsies had similar severity of  rejection characterized ac-
cording to the Banff  criteria[37], with a median RAI score 
of  5, 4.5 and 5 for PSC, PBC and the non-immunological 
group, respectively. 
Immunohistochemical staining procedure: Antigen 
retrieval: heat treatment in Tris EDTA, pH9.0 buffer. 
Primary antibodies: Monoclonal anti CD20, dilution 1:200 
and anti CD56, dilution 1:100, both from Daco, Glos-
trup, Denmark; monoclonal anti CD57, dilution 1/50, 
Nova Castra, Newcastle, United Kingdom; polyclonal 
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P values from the KIR association analysis were corrected 
for multiple testing according to Bonferroni (n = 68).
RESULTS
The disease indications for LTX are shown in Table 1. 
The overall frequency of  histologically confirmed AR in 
the study population was 28%, with significantly higher 
frequency noted in patients with PSC as compared with 
patients transplanted on the basis of  other liver diseases 
(40% vs 24%, OR = 2.2, 95%CI: 1.0-4.6, P = 0.04). All 
episodes of  AR occurred within the first 6 weeks after 
LTX, with a median of  10 days (range 5-40 d). PSC 
patients with concurrent IBD (82%), showed tendency 
to an increased risk of  AR compared to PSC patients 
without IBD (43% vs 25%), but this was not statistically 
significant (P = 0.34). We found no statistically significant 
influence from age or gender on risk of  acute rejection 
(data not shown). For further analyses, recipients were 
grouped according to the occurrence of  AR or non-AR 
and subgrouped according to underlying PSC or not.
PSC-associated HLA alleles confer risk for AR 
independently of underlying disease 
Given the significantly higher frequency of  AR in patients 
with PSC, we specifically analyzed the total study popu-
lation for differences in frequencies of  PSC associated 
HLA-A, -B, -C and -DR alleles between patients with 
AR and without AR. From the HLA alleles previously 
reported to associate with increased PSC susceptibility, an 
increased risk of  AR was detected for recipients positive 
for HLA-B*08 (P = 0.002, OR = 2.5, 95%CI: 1.4-4.6), 
HLA-C*07 (P = 0.001; OR = 2.4; 95%CI: 1.4-4.0) and 
HLA-DRB1*03 (P = 0.03, OR = 1.9, 95%CI: 1.0-3.3) 
(Tables 2-4). For the HLA-DRB1*04 allele, previously 
shown to associate with decreased risk of  PSC, reduced 
risk of  AR in the overall study population was found (P 
= 0.001, OR = 0.2, 95%CI: 0.1-0.5) (Table 4). Notably, 
for HLA-B*08, HLA-C*07 and HLA-DRB1*04 these 
associations remained evident in a subgroup analysis of  
non-PSC recipients only (n = 99) (P = 0.04, P = 0.003 
and P = 0.02, respectively) (Tables 5-7). In PSC recipients 
(n = 44) corresponding P values were 0.002, 0.17 and 0.03 
for HLA-B*08, HLA-C*07 and DRB1*04, respectively.
A dosage effect of  AR prevalence according to the 
PSC-associated HLA alleles was also notable in the total 
recipient population. For HLA-B*08, the frequency of  
AR was 56% in HLA-B*08 homozygous recipients, 39% 
in heterozygous recipients and 21% in recipients lack-
ing HLA-B*08 (P = 0.02). The same was observed for 
the HLA-C*07 allele with AR in 57%, 27% and 18% of  
recipients being homozygous, heterozygous and lacking 
HLA-C*07 respectively (P = 0.003). For HLA-DRB1*04 
the situation was reversed, with the frequency of  AR be-
ing 0% for DRB1*04 homozygous recipients, 12% for 
heterozygous and 35% in recipients lacking the DRB1*04 
allele (P = 0.009). 
rabbit anti CD3, dilution 1/150, Neo Markers, Fremont 
CA, United States. Diluent: Ventana Antibody Diluent, 
Ventana Medical System, Tucson AZ. Incubation time: 
30 min at 37 C. Detection system: Ultra View Univer-
sal DAB- or Alkaline Phosphatase Red-Detection Kits. 
Double stainings: Sequential stainings, one primary an-
tibodies followed by one of  the detection kits, a second 
primary antibody and the other detection kit. Since NK 
cell specific monoclonal antibodies could not be used in 
formalin fixed material, we stained the biopsy samples 
for CD56 and CD57 for detection of  putative NK- and 
NKT cells. 
We calculated the B cell percentage (CD20/CD20 + 
CD3) in the portal infiltrates based on counting of  more 
than 400 B and T cells in the portal areas. Since the 
numbers of  CD56 and CD57 positive cells turned out to 
be very low, we decided to use the absolute number per 
square millimeter. Double immunostaining of  CD56 and 
CD3 was performed in order to distinguish between clas-
sical NK cells (CD3-CD56+) and natural killer T (NKT) 
cells (CD3+CD56+), which represent a distinct lineage of  
T cells and share several surface markers with NK cells. 
Statistical analysis
Statistical analyses were performed using SPSS 18.0 (SPSS 
Inc., Chicago, IL). P values less than 0.05 were considered 
significant. The prevalence of  AR in the different groups 
was compared using the χ 2 test and, where appropriate, 
the Fisher’s exact test. OR and corresponding 95%CI 
were calculated using Woolf ’s formula with Haldane’s 
correction. As have been demonstrated in previous stud-
ies[29,43], there is no significant population stratification in 
the Norwegian population. Comparison of  means for 
KIR gene copy number correlated to AR was performed 
using independent sample t test (after assessment of  nor-
mal distribution). For analysis of  NK cell infiltration in 
biopsies with AR, the one way ANOVA test was used. All 
Table 1  Distribution and frequency of the underlying liver 
disease of 143 liver transplant recipients
Indication for transplantation n  (%)
Autoimmune etiology   65 (45.5)
   Primary sclerosing cholangitis   44 (30.8)
   Primary biliary cirrhosis  14 (9.8)
   Autoimmune hepatitis   7 (4.9)
Viral hepatitis    20 (13.9)
   Hepatitis B   5 (3.5)
   Hepatitis C   15 (10.5)
Other indications   65 (43.9)
   Hepatocellular carcinoma 13 (8.8)
   Secondary liver tumours     7 (4.7)
   Acute hepatic failure     8 (5.4)
   Alcoholic cirrhosis   17 (12.2)
   Cholangiocarcinoma  10 (6.8)
   Budd-Chiari   2 (1.4)
   Cryptogenic cirrhosis   9 (6.1)
   Metabolic liver disease   1 (0.5)
   Polycystic liver disease   2 (1.4)   
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For all other recipient class Ⅰ and class Ⅱ alleles, no 
significant differences between the groups with and with-
out AR were detected.
Effect of HLA class Ⅰ and class Ⅱ mismatching on the 
risk of AR 
HLA-class Ⅰ or class Ⅱ recipient-donor mismatch-
ing (0 vs 1-2 mismatches for HLA-A, HLA-B, HLA-
DR and up to 4 vs 5-6 mismatches for all three epitopes 
combined, respectively) had no significant effects on AR 
incidence (Table 8), neither when all patient-donor pairs 
were analyzed together nor when subgrouped according 
to PSC/non-PSC status (Table 9). 
KIR ligand (i.e., HLA-C and Bw4) disparity does not 
affect the risk of AR after LTX
According to the established differences in KIR bind-
ing strength for HLA-C1 and HLA-C2[21,39,40], genotyped 
HLA-C alleles were classified as either HLA-C1 (Asn80) 
or HLA-C2 (Lys80). The donor HLA-C ligand group 
(i.e., C1 or C2) did not significantly influence the risk of  
AR after LTX. AR was observed in 44% of  LTX with a 
HLA-C2 homozygote donor and in 22% in the hetero-
zygous group compared to 31% in the HLA-C1 homo-
Table 2  Frequencies of human leukocyte antigen-B alleles in the acute cellular rejection group (n  
= 40) and the non-acute cellular rejection group (n  =102) in the total population (missing n  = 1)
HLA-B allele Acute rejection No acute rejection OR 95%CI Uncorrected
n  (alleles) (%) n  (alleles) (%) P  value
*05   0 (0)   8 (4) 0.1 0.0-1.1 0.070
*07 10 (13) 23 (11) 1.2 0.6-2.5 0.690
*08 27 (34) 34 (17) 2.5 1.4-4.6 0.002
*12 12 (14) 27 (13) 1.2 0.6-2.3 0.700
*13   1 (1)   5 (2) 1.1 0.3-4.6 1.000
*14   2 (2)   4 (2) 1.1 0.3-4.6 1.000
*15   6 (7) 28 (14) 0.5 0.2-1.2 0.150
*16   1 (1)   4 (2) 0.7 0.1-3.4 0.510
*17   1 (1)   6 (3) 0.6 0.1-2.8 0.410
*18   1 (1)   6 (3) 0.4 0.1-2.0 0.240
*21   0 (0)   2 (1) 0.5 0.1-4.8 0.360
*22   3 (3)   2 (1) 3.6   0.8-16.4 0.120
*27   4 (5) 10 (5) 1.1 0.4-3.2 1.000
*35   4 (6) 19 (9) 0.7 0.3-1.8 0.230
*37   4 (5)   4 (2) 2.6 0.7-9.1 0.180
*40   4 (5) 19 (9) 0.6 0.2-1.5 0.220
*41   1 (1)   2 (1) 1.5 0.3-9.1 0.870
*47   0 (0)   1 (0.5) 0.8 0.1-9.2 0.530
OR and corresponding 95%CI were calculated using Woolf’s formula with Haldane’s correction; uncorrected P value: 
calculated by the χ 2 test or the Fisher’s exact test where appropriate. HLA: Human leukocyte antigen; AR: Acute 
cellular rejection.
Table 3  Frequencies of human leukocyte antigen-C alleles in the acute cellular rejection group (n  
= 40) and the non-acute cellular rejection group (n  = 102) in the total population (missing n  
= 1)
OR and corresponding 95%CI were calculated using Woolf’s formula with Haldane’s correction; uncorrected P value: 
calculated by the χ 2 test or the Fisher’s exact test where appropriate. HLA: Human leukocyte antigen.
HLA-C allele Acute rejection No acute rejection OR 95%CI Uncorrected
n  (alleles) (%) n  (alleles) (%) P  value
*01   2   (2.5)   8 (3.9) 0.6   0.3-2.9 0.43
*02   2   (2.5) 11 (5.4) 0.5   0.1-1.8 0.24
*03 10 (12.5) 43 (21.1) 0.7   0.3-1.1 0.09
*04   8 (10.0) 24 (11.8) 1.1   0.4-2.2 0.89
*05   8 (10.0) 18 (8.8) 1.0   0.5-2.3 0.76
*06   6   (7.5) 16 (7.8) 1.2   0.5-2.8 0.82
*07 41 (51.2) 62 (30.4) 2.4   1.4-4.0   0.001
*08   2   (2.5)   4 (2.0) 1.1   0.3-4.7 0.54
*12   0 (0)   8 (4.2) 0.2 0.02-1.1 0.07
*14   0 (0)   1 (0.5) 0.9 0.08-9.4 0.72
*15   0 (0)   4 (2.0) 0.3 0.03-2.5 0.26
*16   0 (0)   3 (1.5) 0.4 0.04-3.2 0.31
*17   1   (1.2)   4 (2.0) 0.8   0.2-4.3 0.57
Fosby B et al . HLA and rejection in liver transplantation
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zygous group (P = 0.15). For analysis of  HLA-C KIR 
ligand disparity between recipient and donor, we assessed 
the following possibilities; (1) HLA-C ligand type pres-
ent in the recipient and absent in the donor (i.e., “missing 
self ” model); (2) ligand present in the donor and absent 
in the recipient (i.e., “non-self ” model); and (3) donor 
and recipients homozygous for HLA-C1 and HLA-C2, 
respectively (i.e., complete disparity). We did not detect 
any significant influence from these types of  HLA-C/
KIR ligand disparity on risk of  AR, either in the total 
cohort nor in an analysis stratified according to PSC (P > 
0.05 in all cases).
Classification of  the HLA-B alleles was done accord-
ing to whether they determined the Bw4 (that binds to 
KIR) or Bw6 (that does not bind KIR). We found no in-
fluence of  donor HLA-Bw genotype on AR risk, i.e., AR 
occurred in 29% of  LTX with a HLA-Bw4 homozygote 
donor, in 28% in the heterozygote group and in 35% in 
the HLA-Bw6 homozygote group (P = 0.15). Ligand dis-
parity was defined as recipient carriage of  KIR3DL1 and 
Bw4 (i.e., presence of  inhibition via KIR3DL1-Bw4 inter-
action), with Bw4 absent in the donor (i.e., no inhibition 
via KIR3DL1-Bw4 interaction). There was no significant 
difference in the frequency of  AR between disparate 
(25%) and non-disparate individuals (29%), P = 0.70.
Impact of KIR genes on risk of AR
No significant associations between KIR genotype of  
Table 4  Frequencies of human leukocyte antigen-DRB1 alleles in the acute cellular rejection 
group (n  = 40) and the non-AR group (n  = 103) in the total population
OR and corresponding 95%CI were calculated using Woolf’s formula with Haldane’s correction; uncorrected P value 
is calculated by the χ 2 test or the Fisher’s exact test where appropriate. HLA: Human leukocyte antigen.
HLA-DRB1 Acute rejection No acute rejection OR 95%CI Uncorrected
allele n  (alleles) (%) n  (alleles) (%) P  value
*01 10 (12.5) 23 (11.2) 1.2 0.5-2.5 0.75
*02 15 (18.8) 31 (15.0) 1.3 0.7-2.6 0.44
*03 25 (31.3) 40 (19.4) 1.9 1.0-3.3 0.03
*04   4   (5.0) 46 (22.3) 0.2 0.1-0.5   0.001
*07   7   (8.8) 16   (7.8) 1.2 0.5-2.8 0.78
*08   2   (2.5) 12   (5.8) 0.5 0.1-1.8 0.20
*09   0 (0)   1   (0.5) 0.9 0.1-9.5 0.72
*10   1   (1.3)   4   (1.9) 0.8 0.2-4.4 0.57
*11   1   (1.3)   6   (2.9) 0.6 0.1-2.9 0.37
*12   1   (1.3)   3   (1.5) 1.1 0.2-6.1 0.69
*13 13 (16.3) 21 (10.2) 1.7 0.8-3.6 0.16
*14   1   (1.3)   3   (1.5) 1.1 0.2-6.1 0.69
Table 5  Comparison of the frequencies of human leukocyte antigen-B alleles in the acute cellular 
rejection group (n  = 23) and the non-acute cellular rejection group (n  = 76) in the non-primary 
sclerosing cholangitis population
HLA-B Acute rejection Non acute rejection OR 95%CI Uncorrected
allele n  (alleles) (%) n  (alleles) (%) P  value
*05   0 (0)   4   (2.6) 0.3   0.1-2.9 0.34
*07   6 (13.0) 15   (9.9) 1.4   0.5-3.1 0.54
*08 12 (26.0) 20 (13.2) 2.1   0.8-4.6 0.04
*12   9 (19.6) 20 (13.2) 1.6   0.6-3.4 0.36
*13   1   (2.2)   4   (2.6) 1.0   0.2-5.4 0.67
*14   2   (4.3)   4   (2.6) 1.8     0.5-5.81 0.43
*15   5 (10.9) 21 (13.8) 0.8   0.3-2.1 0.51
*16   1   (2.2)   3   (2.6) 1.0     0.2-5.34 1.00
*17   0 (0)   4   (2.6) 0.3   0.1-2.9 0.63
*18   1   (2.2)   6   (3.9) 0.6   0.1-2.0 1.00
*21   0 (0)   2   (1.3) 0.7   0.1-2.5 1.00
*22   0 (0)   2   (1.3) 0.7 0.11-2.5 0.71
*27   2   (4.3)   7   (4.6) 1.0   0.3-4.0 1.00
*35   4   (8.7) 15   (9.9) 0.8   0.3-2.5 1.00
*37   2   (4.3)   3   (1.9) 2.4     0.4-10.3 0.34
*40   2   (4.3) 17 (11.2) 0.4   0.1-1.4 0.25
*41   1   (2.2)   2   (1.3) 1.9     0.3-11.3 0.56
*47   0 (0)   1   (0.7) 1.0     0.1-11.4 1.00
OR and corresponding 95%CIs were calculated using Woolf’s formula with Haldane’s correction. Uncorrected P 
value is calculated by the χ 2 test or the Fisher’s exact test where appropriate. HLA: Human leukocyte antigen.
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patients and risk of  AR were detected (Tables 2 and 10). 
There was a trend toward the 22 bp deletion variant of  
the KIR2DS4 gene in recipients experiencing AR. This 
was the case in both the overall population and in the 
PSC-stratified analysis, but this finding was not significant 
after correction for the number of  comparisons made in 
the KIR analysis (Bonferroni factor 68, see Tables 10-12). 
There was no significant influence of  recipient copy 
number of  each individual KIR gene and risk of  AR 
(Table 12). 
Immunohistochemical analysis of biopsies with AR 
according to indication for liver transplantation 
Based on the previous suggestions that HLA vs KIR gen-
otype may influence the risk of  AR[22,23,41,42], we assessed 
the frequency of  NK cells in the inflammatory infiltrates 
in AR in PSC and non-PSC patients. We used CD56 and 
CD57 as markers to detect the number and distribution 
of  possible NK cells, along with CD3 and CD20 for the 
counting of  T-and B cells in the formalin fixed biopsies. 
Both epithelial cells in small bile ducts and scattered spin-
dle shaped cells and lymphocyte-like cells were CD56-
Table 6  Comparison of the frequencies of human leukocyte antigen-C alleles in the acute cellular 
rejection group (n  = 23) and the non-acute cellular rejection group (n  = 76) in the non-primary 
sclerosing cholangitis population
OR and corresponding 95%CI were calculated using Woolf’s formula with Haldane’s correction. Uncorrected P value 
calculated by the χ 2 test or the Fisher’s exact test where appropriate. HLA: Human leukocyte antigen.
HLA-C Acute rejection No acute rejection OR 95%CI Uncorrected
allele n  (alleles) (%) n  (alleles) (%) P  value
*01   1   (2.2)   5   (3.3) 0.9 0.16-4.27 1.00
*02   1   (2.2)   7   (4.6) 0.6 0.11-2.53 0.68
*03   4   (8.7) 34 (22.4) 0.4 0.13-0.93 0.06
*04   7 (15.2) 21 (13.8) 1.2 0.45-2.61 0.81
*05   6 (13.0) 12   (7.9) 1.8 0.55-3.74 0.38
*06   3   (6.5) 12   (7.9) 0.9 0.27-2.74 1.00
*07 23 (50.0) 40 (26.3) 2.8 1.42-5.42   0.003
*08   2   (4.3)   4   (2.6) 1.9 0.34-5.89 0.63
*12   0 (0)   6   (3.9) 0.2 0.02-1.62 0.34
*15   0 (0)   4   (2.6) 0.4 0.04-2.94 0.58
*16   0 (0)   3   (2.0) 0.5 0.05-3.97 0.32
*17   1   (2.2)   4   (2.6) 1.1 0.19-5.46 1.00
Table 7  Comparison of the frequencies of human leukocyte antigen-DRB1 alleles in the acute 
cellular rejection group (n  = 23) and the non-acute cellular rejection group (n  = 76) in the non- 
primary sclerosing cholangitis population
OR and corresponding 95%CIs were calculated using Woolf’s formula with Haldane’s correction. Uncorrected P 
value is calculated by the χ 2 test or the Fisher’s exact test where appropriate. HLA: Human leukocyte antigen.
HLA-DRB1 Acute rejection No acute rejection OR 95%CI Uncorrected
allele n  (alleles) (%) n  (alleles) (%) P  value
*01   7 (15.2) 18 (11.8) 1.4 0.6-3.4 0.55
*02   8 (17.4) 23 (15.1) 1.2 0.5-2.8 0.46
*03 13 (28.2) 24 (15.8) 2.5 1.9-5.4 0.05
*04   3   (6.5) 35 (23.0) 0.3 0.1-0.9 0.02
*07   6 (13.0) 12   (7.9) 1.8 0.7-4.8 0.29
*08   2   (4.3) 10   (6.6) 0.7 0.2-2.7 0.73
*10   0 (0)   3   (2.0) 0.5 0.1-4.2 0.59
*11   1   (2.2)   6   (3.9) 0.7 0.1-3.7 1.00
*12   1   (2.2)   3   (2.0) 1.4 0.2-7.9 0.93
*13   7 (15.2) 15   (9.9) 1.7 0.7-4.2 0.31
*14   0 (0)   3   (2.0) 0.5 0.1-4.2 1.00
Table 8  Data on human leukocyte antigen mismatches on the 
risk of acute cellular rejection after liver transplantation  n  (%)
Locus MM (n) Non-AR group 
(n  = 102)
AR group 
(n  = 41)
P  value
HLA-A 1-2 86 (84.3)   38 (92.7) 0.18
0 16 (15.7)   3 (7.3)
HLA-B 1-2 97 (95.1)   41 (100) 0.15
0 5 (4.9) 0 (0)
HLA-DR 1-2 94 (92.2)   40 (97.6) 0.21
0 8 (7.8)   1 (2.4)
A, B, DR 0-4 62 (60.8)   19 (47.3) 0.12
5-6 40 (39.2)   22 (53.7)
Uncorrected P values were calculated by the χ 2 test or the Fisher’s exact 
test where appropriate. HLA: Human leukocyte antigen; MM: Mismatch-
es; AR: Acute cellular rejection.
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positive (Figure 1). Bile ducts were positive for CD56 in 
equal fractions in patients with PSC (30%), PBC (30%) 
and other liver diseases (30%). The numbers and type 
of  lymphocytes observed in the AR biopsies obtained 
from patients with PSC, PBC and non-immunological 
liver diseases revealed no significant differences between 
the groups (Table 13). CD56 positive lymphocytes were 
only sporadically detected in the portal tracts. Scattered 
CD57-positive cells were seen in both the portal tracts, 
periportal and sinusoidal areas in a similar fraction of  
patients in all three groups, and there were no statistically 
significant differences between the numbers of  CD57-
positive cells per square millimeter of  liver tissue. Double 
staining, CD3 with immunoperoxidase and diamino-
benzidine, followed by CD57 with alkaline phosphatase, 
showed no CD57-positive cells, indicating that all or 
practically all CD57-positive cells in the liver biopsies 
were CD3+CD57+ NKT cells.
DISCUSSION
The potential importance of  donor-recipient HLA 
matching in LTX is debated. At some centers, including 
our own, resources are still spent providing HLA data for 
liver allograft recipients even though the information is 
not accounted for in the organ allocation process. It has 
been consistently shown that recipients with PSC have 
an increased AR risk compared to recipients with other 
underlying liver diseases. PSC is strongly HLA-associat-
ed[34,43-45], and in the present analysis we demonstrate that 
this HLA background also associates with increased risk 
of  AR in non-PSC recipients. These results provide an 
impetus to more thoroughly explore the role of  recipient 
immunogenetic determinants on liver graft outcomes, 
rather than overly focusing on genetic matching between 
the donor and the recipient.
The strongest HLA risk factor in PSC is HLA-B*08[43,46]. 
This association is a representative of  the so-called 8.1 
ancestral haplotype (AH8.1), which is defined by a series 
Table 9  Data on human leukocyte antigen mismatches on 
the risk of acute cellular rejection after liver transplantation, 
according to primary sclerosing cholangitis or non-primary 
sclerosing cholangitis  n  (%)
Locus MM Non-AR group AR group P  value
(n) (PSC, n  = 26) (PSC) n  = 17)
 (Non-PSC, n  = 76) (Non-PSC) n  = 24)
HLA-A
(PSC) 1-2 20 (57.1) 15 (42.9)  0.35
0   6 (75.0)   2 (25.0)
(non-PSC) 1-2 65 (73.9) 23 (26.1) 0.18
0 11 (92.7) 1 (7.3)
HLA-B
(PSC) 1-2 25 (59.5) 17 (40.5) 0.41
0     1 (100.0) 0 (0.0)
(non-PSC) 1-2 73 (75.3) 24 (24.7) 0.32
0     3 (100.0) 0 (0.0)
HLA-DR
(PSC) 1-2 26 (61.9) 16 (38.1) 0.44
0 0 (0.0)     1 (100.0)
(non-PSC) 1-2 67 (74.4) 23 (25.6) 0.27
0   9 (90.0)   1 (10.0)
A, B, DR
(PSC) 5-6 12 (54.5) 10 (45.5) 0.42
0-4 14 (66.7)   7 (33.3)
(non-PSC) 5-6 29 (67.4) 14 (32.6) 0.08
0-4 47 (82.4) 10 (17.6)
Uncorrected P values were calculated by the χ 2 test or the Fisher’s exact 
test where appropriate. HLA: Human leukocyte antigen; PSC: Primary 
sclerosing cholangitis; MM: mismatches; AR: acute cellular rejection. 
Table 10  Data on the relationship between killer immuno-
globulin-like receptor gene phenotype (presence/absence of 
gene) in the recipient and the risk of acute cellular rejection 
after liver transplantation in the total patient population 
Recipient KIR  gene phenotype Incidence of AR P value
2DL1    Negative (n = 3)   0% 0.37
   Positive (n = 140) 29%
2DL2    Negative (n = 79) 28% 0.92
   Positive (n = 64) 29%
2DL3    Negative (n = 10) 20% 0.44
   Positive (n = 133) 28%
2DL4    Negative (n = 0) - -
   Positive (n = 143) 29%
2DL5    Negative (n = 79) 32% 0.27
   Positive (n = 64) 24%
2DP1    Negative (n = 3)   0% 0.54
   Positive (n = 140) 31%
2DS1    Negative (n = 91) 32% 0.24
   Positive (n = 52) 20%
2DS2    Negative (n = 76) 27% 0.85
   Positive (n = 67) 29%
2DS3    Negative (n = 108) 28% 0.79
   Positive (n = 35) 31%
2DS4DEL1    Negative (n = 23)   9% 0.03
   Positive (n = 120) 31%
2DS4WT2    Negative (n = 77) 27% 0.84
   Positive (n = 66) 29%
2DS4TOTA3    Negative (n = 3)   0% 0.67
   Positive (n = 140) 29%
2DS5    Negative (n = 104) 32% 0.47
   Positive (n = 39) 24%
3DL1E44    Negative (n = 3)   0% 0.61
   Positive (n = 140) 29%
3DL1E95    Negative (n = 3)   0% 0.62
   Positive (n = 140) 28%
3DL2    Negative (n = 0) - -
   Positive (n = 143) 29%
3DL3    Negative (n = 0) - -
   Positive (n = 143) 29%
3DP1    Negative (n = 0) - -
   Positive (n = 143) 29%
3DS1    Negative (n = 91) 31% 0.39
   Positive (n = 52) 25%
12DS4DEL refers to the 22-bp deletion variant of 2DS4; 22DS4WT refers to 
the full-length form of the gene; 32DS4TOT refers to the total number of 
2DS4, i.e., 2DS4DEL and 2DS4WT combined; 4,53DL1E4 and 3DL1E9 re-
fers to exon 4 and 9 of the 3DL1 gene respectively. The various KIR genes 
genotyped are listed in the leftmost column. Genes with S in the name 
(e.g., KIR2DS4) encode activating KIRs, genes with L in the name (e.g., 
KIR3DL1) encode inhibiting KIRs and genes with a P in the name (e.g., 
KIR3DP1) are pseudogenes. Uncorrected P value is calculated by the χ 2 
test or the Fisher’s exact test where appropriate. KIR: Killer immunoglobu-
lin-like receptor; AR: Acute cellular rejection.
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Table 11  Data on the relationship between killer immuno-
globulin-like receptor gene phenotype in the recipient and 
the risk of acute cellular rejection after liver transplantation 
in patients with primary sclerosing cholangitis compared with 
patients without primary sclerosing cholangitis
Recipient KIR  gene phenotype Incidence of AR P value
2DL1
   (PSC) -
      Negative (n = 0) -
      Positive (n = 4) 40%
   (other) 1.00
      Negative (n = 3)   0%
      Positive (n = 96) 25%
2DL2
   (PSC) 0.37
      Negative (n = 23) 33%
      Positive (n =21) 48%
   (other) 0.71
      Negative (n = 54) 26%
      Positive (n = 45) 22%
2DL3
   (PSC) -
      Negative (n = 0) -
      Positive (n = 44) 40%
   (other) 1.00
      Negative (n = 10) 20%
      Positive (n = 89) 24%
2DL4
   (PSC) -
      Negative (n = 0) - 
      Positive (n = 44) 40%
   (other) -
      Negative (n = 0) -
      Positive (n = 99) 24%
2DL5
   (PSC) 0.17
      Negative (n = 28) 48%
      Positive (n = 16) 25%
   (other) 0.81
      Negative (n = 51) 25%
      Positive (n = 48) 22%
2DP1
   (PSC) -
      Negative (n = 0) -
      Positive (n = 44) 40%
   (other) 1.00
      Negative (n = 3)   0%
      Positive (n = 96) 25%
2DS1
   (PSC) 0.14
      Negative (n = 13) 26%
      Positive (n = 31) 20%
   (other) 0.51
      Negative (n = 60) 26%
      Positive (n = 39) 20%
2DS2
   (PSC) 0.37
      Negative (n = 23) 33%
      Positive (n = 21) 48%
   (other) 0.48
      Negative (n = 54) 26%
      Positive (n = 45) 20%
2DS3
   (PSC) 0.78
      Negative (n = 34) 41%
      Positive (n = 11) 36%
   (other) 0.57
      Negative (n = 76) 22%
      Positive (n = 25) 28%
2DS4DEL1
   (PSC) 0.11
      Negative (n = 8) 38%
      Positive (n = 36) 43%
   (other) 0.10
      Negative (n = 15) 7%
      Positive (n = 85) 27%
2DS4WT2
   (PSC) 0.81
      Negative (n = 21) 38%
      Positive (n = 23) 42%
   (other) 0.71
      Negative (n = 56) 22%
      Positive (n = 43) 26%
2DS4TOTA3
   (PSC) -
      Negative (n = 0) -
      Positive (n = 44) 40%
   (other) 1.00
      Negative (n = 3) 0%
      Positive (n = 96) 25%
2DS5
   (PSC) 0.46
      Negative (n = 34) 43%
      Positive (n = 10) 30%
   (other) 0.56
      Negative (n = 69) 25%
      Positive (n = 30) 20%
3DL1E44
   (PSC) -
      Negative (n = 0) -
      Positive (n = 44) 40%
   (other) -
      Negative (n = 0) -
      Positive (n = 99) 25%
3DL1E95
   (PSC) -
      Negative (n = 0) -
      Positive (n = 44) 40%
   (other) 1.00
      Negative (n = 3)   0%
      Positive (n = 96) 25%
3DL2
   (PSC) -
      Negative (n = 0) -
      Positive (n = 44) 40%
   (other) -
      Negative (n = 0) -
      Positive (n = 98) 24%
3DL3
   (PSC) -
      Negative (n = 0) -
      Positive (n = 44) 40%
   (other) -
      Negative (n = 0) -
      Positive (n = 99) 24%
3DP1
   (PSC) -
      Negative (n = 0) -
      Positive (n = 44) 40%
   (other) -
      Negative (n = 0) -
      Positive (n = 99) 24%
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of  correlated genetic variants within the HLA, includ-
ing also the HLA-C*07 and DRB1*03 alleles[44,45,47]. The 
AH8.1 has profound influence on immune function, as 
also underscored by previously reported associations 
with a wide range of  immune-mediated diseases[44,45]. 
Results in the present study account for both HLA-B*08 
and HLA-C*07 and suggest that the underlying effect 
represented by these associations localizes in or near 
these neighboring genes. The dosage effect observed for 
the PSC associated alleles is also highly supportive of  a 
true effect, i.e., with an AR frequency of  56% and 57%, 
respectively, in homozygous individuals, as compared 
with 21% and 18%, respectively, in individuals without 
HLA-B*08 and HLA-C*07. Importantly, the effect of  
AH8.1 on AR risk was not restricted to patients with 
PSC, suggesting that the immunological abnormalities 
in AH8.1 carriers[45] is of  general importance for the 
pathophysiology in AR. The present results reproduce a 
previously reported association reported between AH8.1 
and AR in liver transplantation[12,48]. There have also been 
notions of  AH8.1 in determining graft survival in kidney 
transplantation[49]. It is thus timely to explore the immu-
nological basis of  this association and the relationship 
between AR and autoimmunity associations related to the 
AH8.1 haplotype. 
Further support of  recipient-related immunogenetic 
determinants for AR holds true for the DRB1*04 associa-
tions, which protect against PSC as well as AR in patients 
with and without PSC. The AR frequency of  individuals 
without DRB1*04 was 35% (comparable to the overall 
AR frequency of  28%), while dropping to 12% and 0% 
for the presence of  one and two DRB1*04 alleles, re-
spectively, suggesting a dosage effect of  the protective 
mechanisms represented by the DRB1*04 haplotype. A 
similar relationship has been noted for type 1 diabetes in 
kidney transplantation[50]. While DRB1*04 is a strong risk 
factor for type 1 diabetes[51], type 1 diabetic recipients of  
diverse ethnicities who carry DRB1*04 experience im-
proved graft survival[50]. A similar shared involvement has 
also been reported for non-HLA risk loci in autoimmune 
risk loci, e.g., for the cytotoxic T-lymphocyte antigen 4 
(CTLA4) gene[52-54]. Most likely the ongoing character-
ization of  shared genetic risk factors between different 
autoimmune diseases should incorporate recipient factors 
for allograft-targeted immune reactions[55], for instance by 
means of  screening large recipient populations with and 
without AR using the Immunochip[43,56].
The precision and homogeneity of  the diagnosis of  
AR is critical for further studies of  the genetics of  AR 
along suggested lines. In the present study, great care was 
taken to include only biopsy proven cases of  AR, and the 
resulting recipient group with AR thus consisted of  Banff  
RAI 3-6 cases with only two exceptions (who showed RAI 
> 6 in their biopsies). Cases with different etiologies with 
potentially similar immune manifestations (e.g., ischemia/
reperfusion related injuries, biliary pathologies and infec-
tions, including early HCV recurrence) were systematically 
excluded. A multitude of  immunological mechanisms are 
at play in the allograft during the first weeks after liver 
transplantation, and lack of  precision in diagnosis of  AR 
will diminish power considerably in genetic association 
studies[57,58]. Ideally, data on confounders and rejection 
characteristics should be prospectively collected, not ret-
rospectively as in the present analysis. Lack of  statistical 
power and phenotypic heterogeneity probably underlies 
the conflicting results of  AR associations for many non-
HLA loci investigated [e.g., interleukin 10 (IL-10)[59-63], 
3DS1
   (PSC) 0.42
      Negative (n = 31) 44%
      Positive (n =13) 31%
   (other) 0.81
      Negative (n = 61) 25%
      Positive (n = 40) 23%
12DS4DEL refers to the 22-bp deletion variant of 2DS4; 22DS4WT refers to 
the full-length form of the gene; 32DS4TOT refers to the total number of 
2DS4, e.g., 2DS4DEL and 2DS4WT combined; 4,53DL1E4 and 3DL1E9 re-
fers to exon 4 and 9 of the 3DL1 gene respectively. The various KIR genes 
genotyped are listed in the leftmost column. Genes with S in the name 
(e.g., KIR2DS4) encode activating KIRs, genes with L in the name (e.g., 
KIR3DL1) encode inhibiting KIRs and genes with a P in the name (e.g., 
KIR3DP1) are pseudogenes. Uncorrected P value was calculated by the χ 2 
test or the Fisher’s exact test where appropriate. KIR: Killer immunoglob-
ulin-like receptor; AR: Acute cellular rejection; PSC: Primary sclerosing 
cholangitis.
Table 12  Killer immunoglobuline-like receptor gene copy 
number of the recipient and acute cellular rejection after liver 
transplantation
KIR  gene AR Non-AR P value
mean copy number 
(95% CI)
mean copy number 
(95%CI)
KIR2DL1 1.69 (1.54-1.84) 1.64 (1.53-1.76) 0.64
KIR2DL2 0.52 (0.34-0.71) 0.53 (0.40-0.65) 0.97
KIR 2DL3 1.50 (1.30-1.70) 1.45 (1.33-1.58) 0.69
KIR 2DL4 2.10 (2.00-2.19) 1.98 (1.91-2.05) 0.06
KIR 2DL5 0.50 (0.27-0.73) 0.63 (0.49-0.78) 0.32
KIR 2DP1 1.71 (1.57-1.86) 1.70 (1.59-1.81) 0.89
KIR 2DS1 0.26 (0.12-0.40) 0.43 (0.33-0.54) 0.08
KIR 2DS2 0.62 (0.30-0.43) 0.54 (0.41-0.66) 0.56
KIR 2DS3 0.29 (0.13-0.44) 0.32 (0.20-0.40) 0.77
KIR 2DS4DEL1 1.17 (1.01-1.32) 1.08 (0.94-1.21) 0.45
KIR 2DS4WT2 0.55 (0.36-0.73) 0.48 (0.37-0.59) 0.53
KIR 2DS4TOT3 1.74 (1.60-1.88) 1.56 (1.45-1.67) 0.06
KIR 2DS5 0.21 (0.08-0.35) 0.32 (0.22-0.42) 0.25
KIR 3DL1E44 1.74 (1.60-1.88) 1.57 (1.46-1.67) 0.08
KIR 3DL1E95 1.74 (1.60-1.88) 1.56 (1.46-1.67) 0.06
KIR 3DL2 - - -
KIR 3DL3 - - -
KIR 3DP1 - - -
KIR 3DS1 0.33 (0.30-0.51) 0.40 (0.30-0.51) 0.47
The various KIR genes genotyped are listed in the leftmost column. Genes 
with S in the name (e.g., KIR2DS4) encode activating KIRs, genes with L 
in the name (e.g., KIR3DL1) encode inhibiting KIRs and genes with a P 
in its name (e.g., KIR3DP1) are pseudogenes. Statistical comparison was 
performed using the independent sample t test. 12DS4DEL refers to the 
22-bp deletion variant of 2DS4; 22DS4WT refers to the full-length form of 
the gene; 32DS4TOT refers to the total number of 2DS4, i.e., 2DS4DEL and 
2DS4WT combined; 4,53DL1E4 and 3DL1E9 refers to exon 4 and 9 of the 
3DL1 gene respectively. KIR: Killer immunoglobulin-like receptor; AR: 
Acute cellular rejection.
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IL-4 and IL-4 receptor[61,64], IL-6[65,66], chemokine receptor 
2 (CCR2)[67], CCR5[67-69], and intercellular adhesion mole-
cule-1 (ICAM1)[70,71]]. The present study is also underpow-
ered to detect non-HLA associations for a complex trait 
like AR[72], but of  the same size as those first reporting on 
what has later shown to be consistent HLA associations 
in other diseases[46,73]. Similarly, it cannot be excluded that 
lack of  AR association for rare HLA alleles in the present 
analysis may be due to type Ⅱ statistical errors.
Some studies have suggested a beneficial effect of  
HLA matching in LTX[12,48], others have found HLA 
matching to be detrimental or even exerting a dualistic 
effect[74]; being beneficial regarding AR, but detrimental 
to graft/patient survival. In most studies, however, HLA 
compatibility has not proven to have significant impact 
on outcome after LTX, and HLA genotype is presently 
not taken into account in the donor selection protocols. 
Data in the present population supports the latter con-
clusion, but also raises the possibility that recipient HLA 
type may be of  consequence for individualized adjust-
ment of  the immunosuppressive regimens if  findings are 
confirmed in future studies. Donor-recipient HLA mis-
matching has previously been reported to be of  greater 
importance in non-autoimmune liver diseases where pri-
mary HLA associations do not exist[12]. A more thorough 
dissection of  the HLA-related risk for AR on the side of  
the recipient only, may thus help clarify HLA determi-
nants on the donor side of  relevance to donor-recipient 
matching. 
NK cells have been suggested to engage in the devel-
opment of  liver allograft tolerance[75-77], and animal ex-
periments have suggested that NK cells infiltrate the liver 
Figure 1  Immunoenzyme stainings in a liver biopsy from a transplanted primary sclerosing cholangitis patient with acute cellular rejection scored ac-
cording to the Banff criteria as RAI 5 (panels A-C), and from a transplanted control patient (secondary liver metastases) with the same grade of cellular 
rejection (panels D-F). Panels A and D show double immunoenzyme staining for CD3 (red) and CD56 (brown, arrows) in a portal area. Panels B and E show immu-
noperoxidase staining for CD57 (brown, arrows) in a portal area. Panels C and F show CD56-staining of bile ducts (arrows). Only scattered CD56- and CD57 positive 
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graft before T lymphocytes[78]. Inspired by work in auto-
immune diseases[16], a series of  studies have assessed the 
impact of  donor and recipient genetic variation relevant 
to NK cell activation on risk of  AR. While some stud-
ies suggest that this interaction may influence the risk of  
AR after LTX[22,23,41], other studies have failed to support 
this[19,20]. A major problem in designing the statistical anal-
ysis of  HLA-KIR interactions, is that biological correlates 
are poorly defined and the number of  potentially relevant 
interactions is thus high. According to conservative Bon-
ferroni-thresholds for statistical significance, none of  the 
reported associations remain significant. This is also the 
case for the present dataset. In an analysis accounting for 
the known biological differences between the HLA-C1 
(weak inhibition via KIR) and HLA-C2 (strong inhibi-
tion via KIR)[16], we were unable to detect an influence of  
the HLA-C2 variant on AR risk[20,21]. Based on previous 
studies reporting an increased frequency of  NK cells in 
the portal infiltrate of  patients with PSC when compared 
with other liver diseases[79,80], we wanted to examine if  
similar findings were present in rejection infiltrates in liver 
transplants. Since the use of  NK cell specific monoclonal 
antibodies was unsuccessful in formalin-fixed material, 
we used antibodies to CD56 and CD57 to detect putative 
NK- and NKT cells. The extremely low number of  CD56 
positive cells in biopsies from patients with AR does not 
exclude the possibility that these cells contribute to im-
mune an immune reaction primarily driven by the infiltra-
tion of  T cells. However, the sum of  evidence suggests 
that a genetically determined NK cell hyperreactivity is 
unlikely to play a major pathogenetic role in AR in LTX. 
In conclusion, we detected a significant impact from 
PSC-associated HLA variants on risk of  AR. The find-
ings are similar in PSC and non-PSC recipients and pro-
vide important confirmatory support to previous studies 
in LTX and kidney transplantation, together serving as a 
basis for further studies of  the underlying mechanisms. 
In addition, we propose that there is a need to query ge-
netic risk of  AR along the model of  other immune medi-
ated diseases. This with spescial focus on   recipients, and 
aiming for comprehensive genetic coverage by means of  
genome-wide association studies or targeted genotyping 
arrays (e.g., the Immunochip) in adequately sized study 
populations. 
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